Navigation Links
Targeting cancerous vessels
Date:1/4/2010

By lowering the level of a neuronal protein, researchers halted the growth of blood vessels that tumors rely on for survival. The findings are reported online in the Journal of Experimental Medicine (www.jem.org) on Jan. 4.

Formerly known for its effects on neuronal growth, the team found that the protein {delta}-catenin is also produced by cells in human blood vessels. By diminishing {delta}-catenin expression, the team disrupted vessel development, or angiogenesis, associated with inflammation in tumors and wounds. As expected, samples of human lung tumors expressed more {delta}-catenin than the surrounding tissues. And normal angiogenesis remained the same regardless of {delta}-catenin.

Because blocking {delta}-catenin stunts only inflammation-induced angiogenesis, the protein may be a promising anti-cancer target, says Charles Lin, an author on the study at Vanderbilt University Medical Center in Tennessee.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert  

Page: 1

Related medicine news :

1. Targeting brain cancer cell metabolism may provide new treatment
2. With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care
3. First live targeting of tumors with RNA-based technology
4. Wistar researchers show targeting normal cells in tumors slows growth
5. Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy's Video-Based Situational Assessments
6. DNA test could be key to targeting treatments for head and neck cancer
7. Another Report Finds Swine Flu Targeting the Young
8. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
9. HIV Atlas Shows Virus Targeting Minorities
10. Targeting tumor behavior may lead to new liver cancer drugs
11. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Targeting cancerous vessels
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: